Rocket Lab Corporation

Thesis

Rocket Lab is the only proven non-SpaceX end-to-end space company and its operating inflection is real — Q1 2026 revenue grew 63.5% to $200.3M with a record $2.2B backlog — but at ~$67 (~$42B market cap, ~60x TTM sales) the price already assumes near-flawless Neutron execution plus a seamless $8B debt-funded Iridium integration. Our probability-weighted value is roughly $17/share and even our bull case returns approximately zero from today's price, so this publishes as a pre-registered watchlist thesis, not a buy: we would own it in the mid-teens to low-$20s. The operating thesis is falsified if Neutron has not flown successfully by mid-2027, backlog prints below $1.8B for two straight quarters, or pre-Neutron revenue growth decays below 20% YoY.

Why Now

The operating inflection the theme research flagged is confirmed in the filings. Q1 2026 revenue was $200.3M, up 63.5% YoY and above the top of the company's own $185–200M guide (10-Q for the quarter ended 2026-03-31, filed ~2026-05-08), against FY2025 revenue of $601.8M, itself up ~38% from $436M in 2024 (10-K FY2025). GAAP gross margin reached 38.2% in Q1 2026 — versus the mid-20s as recently as 2024 — and adjusted EBITDA narrowed to −$11.8M on a $800M annualized run-rate. Guidance for Q2 2026 of $225–240M implies 56–66% YoY growth (Q1 2026 earnings release, 2026-05-07). This is not a story stock waiting for revenue; the revenue is arriving.

Demand evidence is the strongest part. Backlog hit a record $2.2B at Q1 2026, up 20.2% QoQ and roughly double a year earlier, and the company signed 36 new launch contracts in the quarter — 31 Electron/HASTE plus five dedicated Neutron missions sold before the vehicle has flown — more launches sold in one quarter than in all of 2025 (Q1 2026 release and earnings call). Customers are pre-committing to Neutron through 2029, which is about as close as this industry gets to third-party validation of a rocket still on the test stand.

What makes this a decision point rather than a victory lap is the tape. The stock peaked at $150.23 on 2026-05-27 and has since fallen ~55% to $67.28 (2026-07-23 close) on three real developments: Neutron slipped a second time in ~14 months to a Q4 2026 debut after a Stage 1 propellant-tank test failure traced to a defective third-party composite hand-layup process; SpaceX's June 12, 2026 Nasdaq IPO destroyed Rocket Lab's scarcity value as the only investable pure-play; and management announced an ~$8B cash-and-stock acquisition of Iridium ($54/share, $3.6B bridge facility, stock collar floored at $67.50) that converts a $1.3B net-cash growth story into a levered integration story. The question this thesis answers is whether a 55% drawdown makes the best operator in the theme buyable. Our answer, with the math shown below, is: not yet.

Business Quality

The moat is execution scarcity. Orbital launch is a business where nearly every entrant fails, and Rocket Lab is the only company outside SpaceX with a proven high-cadence orbital vehicle (50+ successful Electron missions, record annual cadence in 2025) plus a full merchant space-systems stack: satellite buses (Photon/Flatellite), solar cells (SolAero), separation systems (PSC), flight software (ASI), optical terminals (Mynaric) and EO/IR payloads (Geost). Space systems is now the majority of revenue, meaning the company already makes money selling the picks and shovels of the constellation build-out rather than depending on launch alone. That vertical integration is exactly what customers like the Space Development Agency and Golden Dome-era defense programs are paying for — witness the $515M SDA prime contract and the pace of 2025–26 defense awards feeding the $2.2B backlog.

Unit economics are improving but not yet proven at the company level. GAAP gross margin of 38.2% in Q1 2026 (43.0% non-GAAP) is up sharply from ~27% in 2024, driven by space-systems mix and Electron pricing (~$8.5M ASP). But the company remains EBITDA-negative (−$11.8M adjusted in Q1 2026, guided to −$20M to −$26M in Q2 as Neutron spend peaks), and the profitability case rests on Neutron: a ~$50–55M-per-flight medium-lift vehicle whose reusability economics are entirely unproven and which has now slipped twice. Competition is asymmetric — SpaceX's Transporter rideshare caps small-launch pricing from above, Starship threatens medium-lift pricing later, and Stoke/Firefly/Relativity are funded challengers for the same NSSL Lane 1 dollars — but none of the challengers has Rocket Lab's flight heritage or backlog.

Capital allocation has been aggressive and, until now, shrewd: management sold stock heavily into strength (weighted diluted shares went from ~506M in Q1 2025 to a guided 629M for Q2 2026, ~24% in five quarters) and used the currency for capability acquisitions while banking $1.48B of cash and securities against only $139M of debt. The Iridium takeover is a different order of bet: ~$8B in cash and stock with a $3.6B bridge — 2.4x the company's entire March-quarter liquidity — to buy ~$800M+ of slow-growing but ~60%-EBITDA-margin recurring satcom revenue. Strategically it completes the launch-to-services stack Peter Beck has pitched for years; financially it trades the pristine balance sheet for integration and refinancing risk at exactly the moment Neutron needs maximum margin for error. We score the business A-quality operations attached to a newly B-/C-quality balance-sheet trajectory.

Financial Base

Reference figures as of 2026-07-23: trailing-twelve-month revenue of $680M, 629.0M diluted shares, net debt of $-1,338M, and a share price of $67.28. Sources:

• 10-Q Q1 FY2026 (quarter ended 2026-03-31), filed ~2026-05-08 — revenue $200.348M (+63.5% YoY), cash & equivalents $1,205.5M, marketable securities $271.3M (current $177.9M + non-current $93.5M), total debt ~$138.7M, 575.768M common shares outstanding, net loss $45.0M
• Q1 2026 earnings release (2026-05-07) — backlog $2.2B (+20.2% QoQ, ~2x YoY); Q2 2026 guidance: revenue $225–240M, GAAP GM 33–35%, adj. EBITDA −$20M to −$26M, weighted average shares 629M; GAAP gross margin 38.2%; adjusted EBITDA −$11.75M
• 10-K FY2025 (year ended 2025-12-31, filed ~2026-02) — FY2025 revenue $601.8M (Q2'25 $144.5M, Q3'25 $155.1M, Q4'25 $179.7M per quarterly filings); TTM = 144.5+155.1+179.7+200.3 = $679.6M
• Share price $67.28 close 2026-07-23 (stockanalysis.com / Yahoo Finance); all-time high $150.23 on 2026-05-27 (Macrotrends) — a ~55% drawdown
• Iridium acquisition: ~$8B cash-and-stock at $54/IRDM share, $3.6B bridge facility, RKLB stock collar floored at $67.50 — July 2026 deal press coverage; terms NOT independently verified against the merger agreement/8-K

Scenario Valuation

Five-year scenario ranges under the published methodology — the tables below are computed from these exact parameters at publication and sealed with this text. What each scenario assumes:

• Loss (10%): Neutron suffers repeated failures or a program-level defect (the composite-tank flaw already caused one slip) while the Iridium bridge closes; a levered, EBITDA-negative company in a post-SpaceX-IPO market loses access to cheap equity and the stock reprices toward asset value.
• Bear (30%): Neutron slips into 2028 and flies rarely; SpaceX rideshare and Starship compress launch pricing; space systems keeps growing but decelerates to high-teens; Iridium integration consumes management attention. Exit at 5x EV/Sales — Iridium's own mature-satcom multiple, generous for a still sub-scale margin profile.
• Base (45%): Neutron debuts Q4 2026–H1 2027 and reaches ~8–12 flights/yr by 2031; space systems compounds ~25%/yr on the $2.2B backlog and defense demand; standalone revenue reaches ~$2.3B (Iridium treated as roughly NPV-neutral — its revenue offset by its debt and stock consideration). Exit at 8x EV/Sales, a deliberate premium to every mature comp (L3Harris ~2.6x, Iridium ~5x) justified only by 20%+ terminal growth; equivalent to ~65x FCF at a 12% margin.
• Bull (15%): Everything works: Neutron becomes the #2 Western launcher at 20+ flights/yr, Golden Dome/NSSL Lane 1 awards land at multi-billion scale, Flatellite constellation revenue arrives, Iridium integrates accretively; revenue reaches ~$3.7B standalone-equivalent. Exit at 12x EV/Sales — a scarcity multiple equal to ~60x FCF at a 20% margin, at the outer edge of defensible against mature comparables.

Published range (present value): $6.55 – $38.49 · probability-weighted expected value $17.05 against $67.28 at drafting (0.25×) · base-case IRR −17.2%/yr. Gates: base IRR ≥ 15% and EV ≥ 1.3× — both passed at publication. Ranges are graded at the 1-year checkpoint and the 5-year horizon. This is a range, not a target.

Sensitivity — present value across growth × exit multiple

The shaded cell is the one today's price of $67.28 most closely implies. Find your own cell — we show our work rather than assert a number.

Kill Conditions

1. 1. Neutron has not achieved a successful orbital flight by 2027-06-30 — i.e., more than two additional quarters of slip beyond the current Q4 2026 target (checkable from launch record / 10-Q program disclosure).
2. 2. Total backlog prints below $1.8B for two consecutive quarters (vs $2.2B at Q1 2026) — burn without replacement, checkable each earnings release.
3. 3. Quarterly revenue YoY growth falls below 20% for two consecutive quarters before first Neutron revenue recognition (vs +63.5% in Q1 2026), checkable from 10-Qs.
4. 4. GAAP gross margin falls below 25% for two consecutive quarters (vs 38.2% in Q1 2026), indicating the mix-driven margin story has reversed.
5. 5. The Iridium deal closes and pro-forma total debt exceeds $4.5B without the $3.6B bridge being termed out within 12 months while consolidated adjusted EBITDA remains negative — checkable from the first post-close 10-Q/8-K.

Risk Register

• Valuation — severe: ~60x EV/TTM sales after a 55% drawdown; our bull case (40% revenue CAGR, 12x exit) still returns roughly 0%/yr from $67, meaning the price embeds outcomes beyond our bull.
• Neutron execution — high: second delay in ~14 months, root-caused to a third-party composite hand-layup defect; reusability economics unproven; each slip defers the NSSL Lane 1 / constellation-launch revenue the multiple depends on.
• Iridium acquisition — high: $3.6B bridge equals 2.4x March-quarter liquidity; buying ~flat-growth satcom dilutes the growth algorithm; collar at $67.50 pins the stock and the market now trades RKLB partly as merger arb.
• SpaceX — high: the June 2026 IPO removed RKLB's public-market scarcity premium and gives the dominant competitor a public currency; Transporter/Starship cap launch pricing from above.
• Dilution — medium: weighted diluted shares grew ~24% in five quarters (506M to guided 629M); the Iridium stock consideration adds more.
• Cash burn — medium: adjusted EBITDA still negative (−$11.8M Q1'26, guided −$20M to −$26M Q2) with peak Neutron capex; mitigated today by $1.48B cash+securities, but that cushion is earmarked for the deal.

Theme Position

Revenue exposure to the space economy is effectively 100% — launch services (Electron, HASTE, Neutron) plus space systems (satellite buses, components, payloads), with the pending Iridium deal adding space-based communications services. Within the theme, Rocket Lab is the purest investable expression of the "end-to-end space infrastructure" sub-thesis: it is the only company besides SpaceX that has actually flown its way into that claim.

Alternatives considered. SpaceX (public since 2026-06-12): the category king and the reason RKLB's scarcity premium collapsed, but it lists at mega-cap scale with Starlink dominating the mix — the superior business, likely the more efficiently priced stock, and it deserves its own thesis rather than a footnote here. Iridium: now a merger-arb position on RKLB's own deal (~$54/share cash-and-stock), not a five-year theme holding. Planet Labs / AST SpaceMobile / Firefly: narrower single-bet exposures (EO data, direct-to-device, unproven launch respectively) with binary risk profiles we can't underwrite at better odds than Neutron. Defense primes (L3Harris, Northrop): real space revenue at sane multiples, but space is a minority of revenue — theme dilution defeats the purpose. Rocket Lab remains the right company for this theme; at $67 it is not yet the right stock, which is exactly the distinction Longview exists to make.

Benchmark

Beating means RKLB total return from publication exceeds QQQ total return over the same 5-year window; our base case implies roughly −17%/yr from $67.28, so we expect RKLB to LOSE to QQQ from today's price and publish this as a watchlist note with a ~$13–20 entry zone where outperformance becomes the defensible expectation. Success means beating QQQ's total window return from publication; the scoreboard grades this thesis against that bar, live, whether we like the answer or not.